MarketFriction

Molbio Diagnostics Ltd

NSE MOLBIO · BSE 544866 · Medical Equipment & Supplies
₹1,513.10 +15.60%
NSE close2026-10-01
52 week range926.35 - 1,686.80
Market cap₹14,470 Cr.
P/E66.6
IPO 2026 · +87% since Price band 20% Delivery 10.6%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Jun 2025Mar 2026Jun 2026
Sales95439399
Expenses105332308
Operating Profit-1010792
OPM %-10%24%23%
Other Income131
Interest299
Depreciation7108
Profit before tax-179176
Tax %-23%28%25%
Net Profit-136657
EPS in Rs-5.955.835.02
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales1,2717763277569711,313
Expenses6764572865527461,061
Operating Profit59531940204226252
OPM %47%41%12%27%23%19%
Other Income158-21-24
Interest352568923
Depreciation124219242636
Profit before tax54925823152188198
Tax %25%27%32%27%26%27%
Net Profit41018716111140145
EPS in Rs2,027.06833.3769.00493.0162.0012.83
Dividend Payout %0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%1%59%35%
Compounded Profit Growth%-19%111%1%
Stock Price CAGR%%%%
Return on Equity%16%15%14%
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital2222211
Reserves3336817378489881,123
Borrowings257105577026346
Other Liabilities21585123157291260
Total Liabilities8068749201,0771,3071,741
Fixed Assets55182189209215257
CWIP100002186
Investments99545495317
Other Assets6436836768139801,160
Total Assets8068749201,0771,3071,741
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity344986838249-38
Cash from Investing Activity-142-87-51-31-98-256
Cash from Financing Activity-192-2031-24-17292
Net Cash Flow10-948-18133-2
Free Cash Flow212355524206-74
CFO/OP78%53%251%39%139%6%
Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6111319417486100
Inventory Days261402885393395286
Days Payable12464201129226130
Cash Conversion Cycle198450877438254256
Working Capital Days75206479239155143
ROCE %41%4%22%21%18%
Aug 2026
Promoters41.29%
FIIs1.51%
DIIs16.36%
Government0.02%
Public40.83%
No. of Shareholders2,33,544

Fundamentals

Market Cap₹ 14,470 Cr.
Current Price₹ 1,256
Stock P/E66.6
Book Value₹
ROCE18.0 %
ROE13.8 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)35%
Compounded Profit Growth (TTM)1%
Standalone figures.
Valuation
Market capRs 17,437 Cr
Enterprise valueRs 17,536 Cr
P/E (TTM)93.15x
Price to book25.52x
Price to sales22.46x
EV / EBITDA54.06x
EV / EBIT62.05x
EV / sales22.59x
Price to cash flow178.33x
Earnings yield1.07%
Profitability
Operating margin (excl. other income)41.13%
Operating margin (incl. other income)41.79%
EBITDA margin41.79%
Pre-tax margin33.21%
Net profit margin24.12%
ROE36.77%
ROCE40.95%
ROA22.28%
ROIC (approx.)26.24%
Tax rate27.38%
Other income / net worth0.75%
Growth
Sales growth (latest year)-38.94%
Profit growth (latest year)-54.32%
Per share
EPS (TTM)Rs 16.24
EPS (latest year)Rs 833.36
Book value per shareRs 59.29
Sales per shareRs 67.36
Cash flow per shareRs 8.48
Free cash flow per shareRs -6.42
Efficiency
Asset turnover0.89x
Fixed asset turnover4.26x
Inventory turnover0.93x
Inventory days392 days
Debtor days113 days
Debtors turnover3.23x
Creditor days130 days
Cash conversion cycle256 days
Working capital days143 days
Leverage
Total debtRs 105 Cr
Cash and bankRs 6 Cr
Net debtRs 99 Cr
Debt to equity0.15x
Net debt / EBITDA0.31x
Interest coverage11.37x
Owners' fund to total sources78.16%
Debt to assets12.06%
Cash flow
Cash from Operating Activity (latest year)Rs 98 Cr
Cash from Investing Activity (latest year)Rs -87 Cr
Cash from Financing Activity (latest year)Rs -20 Cr
Net Cash Flow (latest year)Rs -9 Cr
Free cash flow (latest year)Rs -74 Cr
FCFE (approx.: FCF + change in debt)Rs -225 Cr
Cash from ops / profit, 5 years0.69x
Sales to cash flow7.94x
Statement figures
Net sales (TTM)Rs 776 Cr
Net sales (latest year)Rs 776 Cr
Operating profit excl. other income (latest year)Rs 319 Cr
Other income (TTM)Rs 5 Cr
EBITDA (TTM)Rs 324 Cr
PBDT (TTM)Rs 300 Cr
Profit before tax (TTM)Rs 258 Cr
Tax (latest year)Rs 71 Cr
Net profit (TTM)Rs 187 Cr
Net profit (latest year)Rs 187 Cr
Depreciation (TTM)Rs 42 Cr
Interest (TTM)Rs 25 Cr
Cost of goods sold (latest year)Rs 276 Cr
Total expenditure (latest year)Rs 457 Cr
Total income (latest year)Rs 781 Cr
Share capitalRs 2 Cr
ReservesRs 681 Cr
Shareholders' fundsRs 683 Cr
Total assetsRs 874 Cr
Net blockRs 182 Cr
InvestmentsRs 9 Cr
ReceivablesRs 241 Cr
InventoryRs 296 Cr
Other liabilitiesRs 85 Cr
Shares outstanding (crore)11.52
Ownership
Promoter holding41.29%
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
PeriodMOLBIONifty 50Difference
1 week+21.4%-2.8% +24.2 pts
1 month+43.7%-6.8% +50.4 pts
31 mutual fund schemes hold about ₹695 Cr. Over three months 0 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Kotak Aggressive Hybrid Fund1.40%129
HDFC Pharma and Healthcare Fund1.76%58
Kotak Contra Fund1.02%56
Mirae Asset Healthcare Fund1.45%51
Mirae Asset Flexi Cap Fund1.02%46
Nippon India Pharma Fund0.44%41
HDFC Value Fund0.44%36
Kotak Large Cap Fund0.30%33
Kotak Healthcare Fund4.53%31
ICICI Pru Quality Fund0.94%20
Nippon India Innovation Fund0.60%19
Mirae Asset Small Cap Fund0.30%17
ICICI Pru Exports & Services Fund1.04%16
Kotak Consumption Fund0.91%16
ICICI Pru Exports & Services Fund1.04%16
Motilal Oswal Large Cap Fund0.43%13
Tata India Pharma & Healthcare Fund0.87%13
HDFC Innovation Fund0.37%12
Edelweiss Equity Savings Fund(M0.61%10
Edelweiss Equity Savings Fund(M0.61%9
WOC Pharma and Healthcare Fund0.98%9
HDFC MNC Fund1.51%9
Edelweiss Recently Listed IPO Fund0.59%7
PGIM India Large and Mid Cap Fund0.81%7
WOC Aggressive Hybrid Fund0.91%5

Red flags

F-score 3 of 8
explainHigh accruals Profit exceeded operating cash by 10% of total assets in 2026
explainReceivables outrunning sales Receivables grew 14% vs sales -39% in 2026
lookInventory outrunning sales Inventory grew 12% vs sales -39% in 2026
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2026-09-23India Business Excellence Fund IIIAcquirersell3,000,000SAST Open Market
2026-09-23India Business Excellence Fund IIIAcquirersell3,000,000SAST Open Market
2026-09-23India Business Excellence Fund IIIAcquirersell3,000,000SAST Open Market
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

No quarterly results published.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Poly Medicure Ltd16,67152.112.5 %
Fischer Medical Ventures Ltd2,35596.211.4 %
Tarsons Products Ltd1,7541484.59 %
Q-Line Biotech Ltd1,56927.822.5 %
Laxmi Dental Ltd1,05830.415.0 %
Hemant Surgical Industries Ltd86951.318.9 %
Vasa Denticity Ltd75462.37.54 %
OSEL Devices Ltd69123.624.4 %
Prevest Denpro Ltd46220.524.9 %
QMS Medical Allied Services Ltd41939.012.9 %
Nureca Ltd34980.43.30 %
Aprameya Engineering Ltd20039.712.6 %
Avience Biomedicals Ltd19822.727.0 %
Earkart Limited17936.317.5 %
Vaidya Sane Ayurved Laboratories Ltd17619.615.1 %
No bulk or block deals on record.
No corporate actions on record.
DateTypeWhat it says
2026-09-25Board meeting outcomeOutcome of Board Meeting held on September 25, 2026 for re-appointment of M/s K. S. Kamalakara & Co, Cost Accountants as the Cost Auditor of the Compa...
2026-09-17Concall / analyst meetSchedule of meet to be held on Tuesday, September 22, 2026 at 11.00 A.M.(IST) onwards.
2026-09-12Concall / analyst meetTranscript of the Earnings Call held on September 08, 2026 in relation to the Unaudited Financial Results of the Company for the quarter ended June 30...
2026-09-09UpdatesIntimation regarding change of Corporate Identification Number (CIN) of the Company.
2026-09-08Concall / analyst meetLink of Recording
2026-09-08General UpdatesInvestor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026
2026-09-07Press ReleaseA press release dated September 07, 2026, titled "Press Release for the Quarter ended June 30, 2026.".
2026-09-05Board meeting outcomeMolbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-09-02Concall / analyst meetAn Earnings Conference Call is scheduled on Tuesday, 08th September 2026 at 04.00 P.M. IST to discuss the financial performance of the Company for the...
2026-08-27Board meeting outcomeOutcome of Board Meeting held on August 27, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 25perc in previous 1 monthHigh low price variation greater than 75perc in previous 3 months
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03